navigating u.s. healthcare insurance when treating patients with scd
Published 1 month ago • 18 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
3:16
developing patient-specific mrd markers for predicting and preventing mds relapse post-sct
-
1:34
personalizing treatment of transfusion-dependent anemia in lr-mds
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
1:32
genomic sequencing as a driver of advancements in pediatric hematology
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
2:07
phase i/ii study of edit-301, a novel gene-edited autologous hsc medicine, in patients with scd
-
1:47
shared treatment decision-making
-
1:16
eha/ebmt consensus grading of icaht
-
1:52
investigating luspatercept utilization patterns in lower-risk mds
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
1:34
the future role of ai models in hematology and the need for high-quality data sets
-
1:31
the humanistic and economic burden of transfusion-dependent lr-mds
-
4:43
novel treatments being explored for patients with hemophilia: highlights from isth 2024
-
3:31
relevance of the ipss-r during sct in patients with mds in the molecular classification era
-
3:43
genomic profiling to predict prognosis for patients with hr-smm
-
1:05
the future of managing precursor conditions
-
0:55
the role of rna modifications in mds and aml
-
0:50
management of variant acute promyelocytic leukemia
-
1:28
use of machine learning to predict outcomes for patients with scd
-
1:06
overview of the diagnostic work-up for hemophilia
-
1:23
the importance of myeloma-specific frailty indices in trial design
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond